KRAS mutation

News alerts, weekly reports and conference planners

Entrez ID:

3845

Related biomarkers:

‹

›

KRAS mutation	Biliary Tract Cancer	KRAS mutation	Biliary Tract Cancer	trastuzumab + pertuzumab Resistant: C3 – Early Trials ASCO-GI 2023 - 3 weeks (New C3) trastuzumab + pertuzumab Resistant : C3 ASCO-GI 2023 - 3wk	trastuzumab + pertuzumab Resistant: C3 – Early Trials ASCO-GI 2023 - 3 weeks trastuzumab + pertuzumab Resistant : C3 ASCO-GI 2023 - 3 weeks - (New C3)
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	AGEN2034 + AGEN1181 Sensitive: C3 – Early Trials ASCO-GI 2023 - 3 weeks (New C3) AGEN2034 + AGEN1181 Sensitive : C3 ASCO-GI 2023 - 3wk	AGEN2034 + AGEN1181 Sensitive: C3 – Early Trials ASCO-GI 2023 - 3 weeks AGEN2034 + AGEN1181 Sensitive : C3 ASCO-GI 2023 - 3 weeks - (New C3)
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 3 weeks (New D) alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 3wk	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 3 weeks alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 3 weeks - (New D)
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	cetuximab Resistant: B - Late Trials cetuximab Resistant : B	cetuximab Resistant: B - Late Trials cetuximab Resistant : B
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	trifluridine/tipiracil Sensitive: B - Late Trials trifluridine / tipiracil Sensitive : B	trifluridine/tipiracil Sensitive: B - Late Trials trifluridine / tipiracil Sensitive : B
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	pembrolizumab Sensitive: B - Late Trials pembrolizumab Sensitive : B	pembrolizumab Sensitive: B - Late Trials pembrolizumab Sensitive : B
KRAS mutation	Acute Myelogenous Leukemia	KRAS mutation	Acute Myelogenous Leukemia	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B
KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer	KRAS mutation	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: B - Late Trials bevacizumab + atezolizumab Sensitive : B	bevacizumab + atezolizumab Sensitive: B - Late Trials bevacizumab + atezolizumab Sensitive : B
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	selumetinib Sensitive: B - Late Trials selumetinib Sensitive : B	selumetinib Sensitive: B - Late Trials selumetinib Sensitive : B
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	nivolumab Sensitive: B - Late Trials nivolumab Sensitive : B	nivolumab Sensitive: B - Late Trials nivolumab Sensitive : B
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	erlotinib Resistant: B - Late Trials erlotinib Resistant : B	erlotinib Resistant: B - Late Trials erlotinib Resistant : B
KRAS mutation	Thyroid Gland Medullary Carcinoma	KRAS mutation	Thyroid Gland Medullary Carcinoma	cabozantinib capsule Sensitive: B - Late Trials cabozantinib capsule Sensitive : B	cabozantinib capsule Sensitive: B - Late Trials cabozantinib capsule Sensitive : B
KRAS mutation	Thyroid Gland Medullary Carcinoma	KRAS mutation	Thyroid Gland Medullary Carcinoma	cabozantinib capsule Sensitive: B - Late Trials cabozantinib capsule Sensitive : B	cabozantinib capsule Sensitive: B - Late Trials cabozantinib capsule Sensitive : B
KRAS mutation	Ovarian Cancer	KRAS mutation	Ovarian Cancer	binimetinib Sensitive: B - Late Trials binimetinib Sensitive : B	binimetinib Sensitive: B - Late Trials binimetinib Sensitive : B
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B	durvalumab + tremelimumab Sensitive: B - Late Trials durvalumab + tremelimumab Sensitive : B
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	pembrolizumab + abemaciclib Sensitive: C2 – Inclusion Criteria pembrolizumab + abemaciclib Sensitive : C2	pembrolizumab + abemaciclib Sensitive: C2 – Inclusion Criteria pembrolizumab + abemaciclib Sensitive : C2
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	bevacizumab + PCM-075 Sensitive: C2 – Inclusion Criteria bevacizumab + PCM-075 Sensitive : C2	bevacizumab + PCM-075 Sensitive: C2 – Inclusion Criteria bevacizumab + PCM-075 Sensitive : C2
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	trametinib Sensitive: C2 – Inclusion Criteria trametinib Sensitive : C2	trametinib Sensitive: C2 – Inclusion Criteria trametinib Sensitive : C2
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	afatinib + selumetinib Sensitive: C2 – Inclusion Criteria afatinib + selumetinib Sensitive : C2	afatinib + selumetinib Sensitive: C2 – Inclusion Criteria afatinib + selumetinib Sensitive : C2
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	bevacizumab Sensitive: C2 – Inclusion Criteria bevacizumab Sensitive : C2	bevacizumab Sensitive: C2 – Inclusion Criteria bevacizumab Sensitive : C2
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	eFT226 Sensitive: C2 – Inclusion Criteria eFT226 Sensitive : C2	eFT226 Sensitive: C2 – Inclusion Criteria eFT226 Sensitive : C2
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	VS-6766 Sensitive: C2 – Inclusion Criteria VS-6766 Sensitive : C2	VS-6766 Sensitive: C2 – Inclusion Criteria VS-6766 Sensitive : C2
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	GSK3070785 Sensitive: C2 – Inclusion Criteria GSK3070785 Sensitive : C2	GSK3070785 Sensitive: C2 – Inclusion Criteria GSK3070785 Sensitive : C2
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	anlotinib Sensitive: C2 – Inclusion Criteria anlotinib Sensitive : C2	anlotinib Sensitive: C2 – Inclusion Criteria anlotinib Sensitive : C2
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	sunitinib Sensitive: C2 – Inclusion Criteria sunitinib Sensitive : C2	sunitinib Sensitive: C2 – Inclusion Criteria sunitinib Sensitive : C2
KRAS mutation	Ovarian Cancer	KRAS mutation	Ovarian Cancer	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria VS-6766 + VS-6063 Sensitive : C2	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria VS-6766 + VS-6063 Sensitive : C2
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	bevacizumab + cetuximab Sensitive: C2 – Inclusion Criteria bevacizumab + cetuximab Sensitive : C2	bevacizumab + cetuximab Sensitive: C2 – Inclusion Criteria bevacizumab + cetuximab Sensitive : C2
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	palbociclib + binimetinib Sensitive: C2 – Inclusion Criteria palbociclib + binimetinib Sensitive : C2	palbociclib + binimetinib Sensitive: C2 – Inclusion Criteria palbociclib + binimetinib Sensitive : C2
KRAS mutation	Melanoma	KRAS mutation	Melanoma	trametinib Sensitive: C2 – Inclusion Criteria trametinib Sensitive : C2	trametinib Sensitive: C2 – Inclusion Criteria trametinib Sensitive : C2
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	cetuximab + selumetinib Sensitive: C2 – Inclusion Criteria cetuximab + selumetinib Sensitive : C2	cetuximab + selumetinib Sensitive: C2 – Inclusion Criteria cetuximab + selumetinib Sensitive : C2
KRAS mutation	Acute Myelogenous Leukemia	KRAS mutation	Acute Myelogenous Leukemia	venetoclax Resistant: C3 – Early Trials venetoclax Resistant : C3	venetoclax Resistant: C3 – Early Trials venetoclax Resistant : C3

KRAS mutation

Associations